GlaxoSmithKline's vaccine candidate for the deadly Ebola virus is ready to roll in human trials.
President Obama highlighted a $78.9 million BRAIN Initiative project to improve service members' and veterans' health through the development of nano-scale electrical implants to modulate nerve signaling and record health biomarkers.
AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D of Antibody-Drug Conjugate analysis capabilities.
Plastic surgeons in India were able to convert CT scans of a three-year-old girl suffering with craniosynostosis into a physical replica using a 3-D printer. The realistic, life-size model was then used in practice runs of the surgery.
Advanced Catheter Therapies' venture capital funding round has been oversubscribed, reflecting investor interest in the company's Occlusion Perfusion Catheter for localized drug delivery in the peripheral vasculature.
The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.
ReGenX Biosciences is one of the most intriguing gene therapy biotechs you never heard of. And now the executive team in charge intends to start changing that.
Researchers at Louisiana Tech University say they have harnessed 3-D printing for drug delivery by fabricating bioresorbable filaments enabling targeted delivery of antibiotics or chemotherapeutics.
Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.
Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in a trial update that 12 of 13 evaluable patients with advanced B cell malignancies demonstrated a complete or partial response after being treated with its chimeric antigen receptor (CAR) T cell therapy.